FDA Approves Pfizer's Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions - BioSpace

FDA Approves Pfizer's Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions  BioSpace

NEW YORK--(BUSINESS WIRE)-- Pfizer, Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ...